Many factors contribute to the price that consumers pay for prescription drugs and biologics. These factors include research and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
AbbVie
-
-
Prior to 1994, the term of a U.S. patent was 17 years from the date of issuance. When the Uruguay Round Agreements Act (“URAA”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, the Patent Trial and Appeal Board (“PTAB” or “the Board”) denied institution of Sandoz’s petition for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On the same day that the PTAB instituted review of an AbbVie Biotechnology Ltd. (“AbbVie”) patent covering a method of using adalimumab...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
At the urging of Sandoz Inc. (“Sandoz”), the PTAB instituted review of claims 1, 2, and 5-7 of U.S. Patent No. 9,067,992 (“the ʼ992...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sandoz’s request for inter partes review (“IPR”) of U.S. Patent Numbers 9,512,216 (“the ’216 patent”) and 8,802,100 (“the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, the Federal Circuit affirmed a lower court’s dismissal of AbbVie’s complaint seeking declaratory judgment of invalidity of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]